Literature DB >> 11861826

Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins.

James M Binley1, Rogier W Sanders, Aditi Master, Charmagne S Cayanan, Cheryl L Wiley, Linnea Schiffner, Bruce Travis, Shawn Kuhmann, Dennis R Burton, Shiu-Lok Hu, William C Olson, John P Moore.   

Abstract

In virus-infected cells, the envelope glycoprotein (Env) precursor, gp160, of human immunodeficiency virus type 1 is cleaved by cellular proteases into a fusion-competent gp120-gp41 heterodimer in which the two subunits are noncovalently associated. However, cleavage can be inefficient when recombinant Env is expressed at high levels, either as a full-length gp160 or as a soluble gp140 truncated immediately N-terminal to the transmembrane domain. We have explored several methods for obtaining fully cleaved Env for use as a vaccine antigen. We tested whether purified Env could be enzymatically digested with purified protease in vitro. Plasmin efficiently cleaved the Env precursor but also cut at a second site in gp120, most probably the V3 loop. In contrast, a soluble form of furin was specific for the gp120-gp41 cleavage site but cleaved inefficiently. Coexpression of Env with the full-length or soluble form of furin enhanced Env cleavage but also reduced Env expression. When the Env cleavage site (REKR) was mutated in order to see if its use by cellular proteases could be enhanced, several mutants were found to be processed more efficiently than the wild-type protein. The optimal cleavage site sequences were RRRRRR, RRRRKR, and RRRKKR. These mutations did not significantly alter the capacity of the Env protein to mediate fusion, so they have not radically perturbed Env structure. Furthermore, unlike that of wild-type Env, expression of the cleavage site mutants was not significantly reduced by furin coexpression. Coexpression of Env cleavage site mutants and furin is therefore a useful method for obtaining high-level expression of processed Env.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861826      PMCID: PMC135977          DOI: 10.1128/jvi.76.6.2606-2616.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  97 in total

1.  Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.

Authors:  J A McKeating; A McKnight; J P Moore
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

2.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

Authors:  A Trkola; T Dragic; J Arthos; J M Binley; W C Olson; G P Allaway; C Cheng-Mayer; J Robinson; P J Maddon; J P Moore
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

3.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

4.  Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick-borne encephalitis.

Authors:  F X Heinz; S L Allison; K Stiasny; J Schalich; H Holzmann; C W Mandl; C Kunz
Journal:  Vaccine       Date:  1995-12       Impact factor: 3.641

5.  Endoprotease activities other than furin and PACE4 with a role in processing of HIV-I gp160 glycoproteins in CHO-K1 cells.

Authors:  N M Inocencio; J F Sucic; J M Moehring; M J Spence; T J Moehring
Journal:  J Biol Chem       Date:  1997-01-10       Impact factor: 5.157

6.  Dissociation of gp120 from HIV-1 virions induced by soluble CD4.

Authors:  J P Moore; J A McKeating; R A Weiss; Q J Sattentau
Journal:  Science       Date:  1990-11-23       Impact factor: 47.728

7.  Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions.

Authors:  J Schalich; S L Allison; K Stiasny; C W Mandl; C Kunz; F X Heinz
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

8.  Mutational analysis of the human immunodeficiency virus type 1 env gene product proteolytic cleavage site.

Authors:  V Bosch; M Pawlita
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

9.  Functional contribution of cysteine residues to the human immunodeficiency virus type 1 envelope.

Authors:  E Tschachler; H Buchow; R C Gallo; M S Reitz
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

10.  Identification of the paired basic convertases implicated in HIV gp160 processing based on in vitro assays and expression in CD4(+) cell lines.

Authors:  E Decroly; S Wouters; C Di Bello; C Lazure; J M Ruysschaert; N G Seidah
Journal:  J Biol Chem       Date:  1996-11-29       Impact factor: 5.157

View more
  91 in total

1.  Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.

Authors:  Ralph Pantophlet; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

2.  A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses.

Authors:  Thijs van Montfort; Mark Melchers; Gözde Isik; Sergey Menis; Po-Ssu Huang; Katie Matthews; Elizabeth Michael; Ben Berkhout; William R Schief; John P Moore; Rogier W Sanders
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

Review 3.  Furin at the cutting edge: from protein traffic to embryogenesis and disease.

Authors:  Gary Thomas
Journal:  Nat Rev Mol Cell Biol       Date:  2002-10       Impact factor: 94.444

4.  Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.

Authors:  Ilja Bontjer; Mark Melchers; Dirk Eggink; Kathryn David; John P Moore; Ben Berkhout; Rogier W Sanders
Journal:  J Biol Chem       Date:  2010-09-08       Impact factor: 5.157

5.  HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.

Authors:  Bimal K Chakrabarti; Marie Pancera; Sanjay Phogat; Sijy O'Dell; Krisha McKee; Javier Guenaga; James Robinson; John Mascola; Richard T Wyatt
Journal:  AIDS Res Hum Retroviruses       Date:  2011-01-19       Impact factor: 2.205

6.  HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.

Authors:  Tommy Tong; Ema T Crooks; Keiko Osawa; James M Binley
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

7.  Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.

Authors:  Rajesh P Ringe; Anila Yasmeen; Gabriel Ozorowski; Eden P Go; Laura K Pritchard; Miklos Guttman; Thomas A Ketas; Christopher A Cottrell; Ian A Wilson; Rogier W Sanders; Albert Cupo; Max Crispin; Kelly K Lee; Heather Desaire; Andrew B Ward; P J Klasse; John P Moore
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

8.  Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes.

Authors:  Steven W de Taeye; Gabriel Ozorowski; Alba Torrents de la Peña; Miklos Guttman; Jean-Philippe Julien; Tom L G M van den Kerkhof; Judith A Burger; Laura K Pritchard; Pavel Pugach; Anila Yasmeen; Jordan Crampton; Joyce Hu; Ilja Bontjer; Jonathan L Torres; Heather Arendt; Joanne DeStefano; Wayne C Koff; Hanneke Schuitemaker; Dirk Eggink; Ben Berkhout; Hansi Dean; Celia LaBranche; Shane Crotty; Max Crispin; David C Montefiori; P J Klasse; Kelly K Lee; John P Moore; Ian A Wilson; Andrew B Ward; Rogier W Sanders
Journal:  Cell       Date:  2015-12-17       Impact factor: 41.582

9.  Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.

Authors:  Denise L Kothe; Julie M Decker; Yingying Li; Zhiping Weng; Frederic Bibollet-Ruche; Kenneth P Zammit; Maria G Salazar; Yalu Chen; Jesus F Salazar-Gonzalez; Zina Moldoveanu; Jiri Mestecky; Feng Gao; Barton F Haynes; George M Shaw; Mark Muldoon; Bette T M Korber; Beatrice H Hahn
Journal:  Virology       Date:  2006-11-13       Impact factor: 3.616

10.  Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Authors:  Rogier W Sanders; Mika Vesanen; Norbert Schuelke; Aditi Master; Linnea Schiffner; Roopa Kalyanaraman; Maciej Paluch; Ben Berkhout; Paul J Maddon; William C Olson; Min Lu; John P Moore
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.